- Home
- HBT vs ABSI Comparison
HBT vs ABSI Comparison
Compare HBT & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBT | ABSI |
|---|---|---|
| Founded | 1920 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 997.8M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HBT | ABSI |
|---|---|---|
| Price | $35.68 | $9.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $30.75 | $6.96 |
| AVG Volume (30 Days) | 129.7K | ★ 2.6M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | 7.96 | ★ 10.64 |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | $35.73 | $215.96 |
| Revenue Next Year | $7.01 | $319.10 |
| P/E Ratio | $32.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.36 | $2.24 |
| 52 Week High | $37.51 | $12.06 |
Technical Indicators
Market Signals| Indicator | HBT | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 58.06 | 52.43 |
| Support Level | $35.34 | $8.55 |
| Resistance Level | $37.17 | $12.06 |
| Average True Range (ATR) | 0.73 | 0.55 |
| MACD | -0.25 | 0.03 |
| Stochastic Oscillator | 41.90 | 55.00 |
Price Performance
Historical ComparisonAbout HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.